GPEx®-DERIVED CELL LINE SALE AGREEMENTLine Sale Agreement • November 1st, 2018 • DiaMedica Therapeutics Inc. • Pharmaceutical preparations • New York
Contract Type FiledNovember 1st, 2018 Company Industry JurisdictionThis GPEx®-Derived Cell Line Sale Agreement (this “Agreement”) is made as of this 2nd day of February, 2012 (“Effective Date”), by and between DiaMedica Inc., a Manitoba corporation, with a place of business at 200 – 135 Innovation Drive, Winnipeg, Manitoba, R3T 6A8, Canada (“Client”), and Catalent Pharma Solutions, LLC, a Delaware limited liability company, with a place of business at 14 Schoolhouse Road, Somerset, New Jersey 08873, USA (“Catalent”).
GPEx®-DERIVED CELL LINE SALE AGREEMENTLine Sale Agreement • October 19th, 2018 • DiaMedica Therapeutics Inc. • Pharmaceutical preparations • New York
Contract Type FiledOctober 19th, 2018 Company Industry JurisdictionThis GPEx®-Derived Cell Line Sale Agreement (this “Agreement”) is made as of this 2nd day of February, 2012 (“Effective Date”), by and between DiaMedica Inc., a Manitoba corporation, with a place of business at 200 – 135 Innovation Drive, Winnipeg, Manitoba, R3T 6A8, Canada (“Client”), and Catalent Pharma Solutions, LLC, a Delaware limited liability company, with a place of business at 14 Schoolhouse Road, Somerset, New Jersey 08873, USA (“Catalent”).